Sudapyridine not checked
Shanghai Jiatan Pharmatech Co., Ltd · WX-081
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Sudapyridine (WX-081) will be administered as a loading dose for 2 weeks (450 mg once daily for 7 days, followed by 300 mg once daily for 7 days) and a maintenance dose (150 mg once daily) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for bedaquiline.”In the company’s words, NCT05824871 on ClinicalTrials.gov
- Tested for
- Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB), Rifampicin-Resistant Pulmonary Tuberculosis Patients, TB
- Main trialPhase 3
- “This is a multicenter, randomized, double-blind, active-controlled Phase III study to evaluate the efficacy and safety of Sudapyridine (WX-081) combined with a background regimen (BR) in patients with rifampicin-resistant pulmonary tuberculosis. Approximately 450 participants will be screened over a period of up to 2 weeks and randomized in a 2:1 ratio to receive either Sudapyridine or bedaquiline, in combination with placebo tablets and BR, for 24 weeks. After the treatment period, participants will enter a background regimen period up to Week 72, during which they will continue to receive…”In the company’s words, NCT05824871 on ClinicalTrials.gov
- Other names
- WX-081
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 22 Dec 2025 | A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients | |
| Phase 1Not yet recruiting | 12 Oct 2025 | Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults | |
| Phase 1Recruiting | 12 Dec 2025 | Pharmacokinetic Study of Sudapyridine(WX-081)in Healthy Chinese Subjects | |
| Phase 2Completed | 13 Apr 2022 | Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 | |
| Phase 1Completed | 2 Jul 2020 | Sudapyridine (WX-081) in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026